|
|
In re Maxim Pharmaceuticals, Inc. Securities Litigation
In In re Maxim Pharmaceuticals, Inc. Securities Litigation, Case No. 04 CV 1900 DMS (BLM)(S.D. Cal.), Labaton Sucharow, as Co-Lead Counsel with Schiffrin & Barroway, LLP, represents Lead Plaintiffs William and Lori Milowitz and James Brent Allen in this potential class action case against Maxim that alleges securities fraud claims. The lawsuit seeks to recover damages caused by false and misleading misstatements about Maxim’s key drug in development, Ceplene, between November 2002 and September 2004. Both parties have agreed to a settlement of $1.3 million in cash and $1.3 million in stock paid by the Defendants. The settlement was approved by the Court on September 22, 2006.
|